Musholt Thomas J, Fottner Christian, Weber Matthias M, Eichhorn Waltraud, Pohlenz Joachim, Musholt Petra B, Springer Erik, Schad Arno
Endocrine Surgery, University Medical Center, Gutenberg University Mainz, Langenbeckstr. 1, 55101, Mainz, Germany.
World J Surg. 2010 Nov;34(11):2595-603. doi: 10.1007/s00268-010-0729-4.
Activating mutations of the oncogene BRAF or rearrangements of the tyrosine kinase receptor RET are observed in up to 80% of papillary thyroid carcinomas (PTCs). The predominant BRAF V600E mutation has not been detected in benign thyroid tissue so far, so consequently, this assumedly pathognomonic alteration is qualified to improve the preoperative diagnosis of PTC.
Two hundred ninety preoperatively harvested fine-needle aspiration biopsies (FNABs) underwent routine cytologic assessment. BRAF V600E mutation analysis was performed by mutation-specific PCR using the same cell material; a hybrid-specific RT-PCR assay was used for detection of RET/PTC1 rearrangements. Detected genetic alterations were verified by direct sequencing. Definitive histopathology was obtained in 93/290 lesions following surgery of the respective thyroid nodule.
While cytology alone diagnosed 13/30 malignancies (22 PTCs, 4 FTCs, 1 MTC, 1 UTC, 2 metastases), five additional malignancies were identified by supplementary mutation analysis. Cytology classified eight FNABs as benign, while postoperative histology demonstrated a thyroid malignancy (6 PTCs, 1 FTC, 1 metastasis). In four of these eight cases, the genetic analysis detected a BRAF V600E mutation or a RET/PTC1 rearrangement. Classifying both suspicious and malignant FNAB results as positive cytology results, supplementary genetic testing increased the overall sensitivity of FNAB from 70.4 to 85.7%, the positive predictive value (PPV) from 59.4 to 64.9%, and the negative predictive value (NPV) from 84.0 to 91.3%.
Supplementary mutation analysis of RET and especially of the BRAF V600E mutation in FNABs is a fast and probably cost-effective assay in routine diagnostic setting. Mutation analyses of PTC-specific genetic alterations improve the preoperative identification and prognostic assessment of thyroid malignancies and therefore enable an optimized surgical strategy.
在高达80%的甲状腺乳头状癌(PTC)中可观察到癌基因BRAF的激活突变或酪氨酸激酶受体RET的重排。迄今为止,在良性甲状腺组织中尚未检测到主要的BRAF V600E突变,因此,这种据推测具有病理诊断意义的改变有资格改善PTC的术前诊断。
对290份术前采集的细针穿刺活检(FNAB)样本进行常规细胞学评估。使用相同的细胞材料通过突变特异性PCR进行BRAF V600E突变分析;采用杂交特异性RT-PCR检测RET/PTC1重排。通过直接测序验证检测到的基因改变。在对相应甲状腺结节进行手术后,对93/290个病变进行了明确的组织病理学检查。
仅细胞学诊断出13/30例恶性肿瘤(22例PTC、4例FTC、1例MTC、1例UTC、2例转移瘤),通过补充突变分析又发现了另外5例恶性肿瘤。细胞学将8份FNAB分类为良性,而术后组织学显示为甲状腺恶性肿瘤(6例PTC、1例FTC、1例转移瘤)。在这8例中的4例中,基因分析检测到BRAF V600E突变或RET/PTC1重排。将可疑和恶性FNAB结果均分类为阳性细胞学结果,补充基因检测使FNAB的总体敏感性从70.4%提高到85.7%,阳性预测值(PPV)从59.4%提高到64.9%,阴性预测值(NPV)从84.0%提高到91.3%。
在FNAB中对RET尤其是BRAF V600E突变进行补充突变分析,在常规诊断环境中是一种快速且可能具有成本效益的检测方法。对PTC特异性基因改变进行突变分析可改善甲状腺恶性肿瘤的术前识别和预后评估,从而制定优化的手术策略。